Assessment of mood: Guides for clinicians

Furukawa, Toshi A

doi:10.1016/j.jpsychores.2009.05.003

Cited by 149 publications

(128 citation statements)

References 53 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…The results of this study are associated with depressive symptoms in the general adult population, not with depressive symptoms of a major depressive episode. The PHQ-9, which could screen a major depressive episode, as mentioned in the Subjects and methods section (Furukawa, 2010), enables comparison between the subjects with a major depressive episode and the healthy subjects in terms of childhood abuse, negative stressful life events and temperaments. The diagnostic algorithmic threshold of the PHQ-9 for diagnosing a major depressive episode found 7 subjects (1 male, 6 female) with a major depressive episode, although these diagnoses were tentative because these subjects did not have psychiatric interviews.…”

Section: Comparison Between the Subjects With A Major Depressive Epismentioning

confidence: 99%

The influence of childhood abuse, adult stressful life events and temperaments on depressive symptoms in the nonclinical general adult population

Nakai

Inoue

Toda

et al. 2014

Journal of Affective Disorders

102

View full text Add to dashboard Cite

Background: Previous studies have shown the interaction between heredity and childhood stress or life events on the pathogenesis of major depression. We hypothesized that childhood abuse, affective temperaments, and adult stressful life events interact and influence depressive symptoms in the general adult population and tested this hypothesis in this study. Methods:The 294 participants from the nonclinical general adult population were studied using the Limitations:The subjects of this study were nonclinical. The findings might not be generalized to patients with mood disorders. Conclusions:This study suggests that childhood abuse, especially neglect, indirectly increased depressive symptoms through increased affective temperaments, which, in turn, increase the negative appraisal of stressful life events. An important role of affective temperaments in the effect of childhood abuse and stressful life events on depressive symptoms was suggested.

show abstract

Section: Comparison Between the Subjects With A Major Depressive Epismentioning

confidence: 99%

The influence of childhood abuse, adult stressful life events and temperaments on depressive symptoms in the nonclinical general adult population

Nakai

Inoue

Toda

et al. 2014

Journal of Affective Disorders

102

View full text Add to dashboard Cite

show abstract

“…The current diagnostic tools are symptom driven and include various questions asked when completing the patient history (e.g., "Have you been feeling down, depressed, or blue over the last 2weeks?") or are found in patient-completed questionnaires and scales (e.g., Beck Depression Inventory; Patient Health Questionnaire-9-item [PHQ-9]) [14][15][16]. The high prevalence of MDD suggests that such screening questions and instruments should be a necessary component of every patient history.…”

Section: Diagnosis and Treatment Of Mddmentioning

confidence: 99%

Personalized medicine in major depressive disorder — Opportunities and pitfalls

Miller

O’Callaghan

2013

Metabolism

View full text Add to dashboard Cite

The sequencing of the human genome in the early days of this millennium was greeted with great fanfare as this accomplishment was expected to revolutionize medicine and result in individualized treatments based on the genetic make-up of the patient. The ultimate promise of personalized medicine would be fulfilled with the identification of disease biomarkers that would be widely available for use in diagnosis and treatment. Progress, however, has been slow in providing disease biomarkers or approved diagnostic tests. This is true for major depressive disorder (MDD), despite its prevalence in the general population and the widespread acceptance of its biological basis. Studies using strategies like genome-wide association and candidate gene analyses have identified a number of possible biomarkers of MDD, including serum levels of neurotrophic factors, inflammatory cytokines and HPA axis hormones, but none have proven sufficiently powerful for clinical use. The lack of biologically based tests available for use in identifying patients with MDD is a significant impediment to personalized and more effective treatment, because it means diagnosis continues to be driven by subjective symptoms. While genetic studies of MDD have not yet led to diagnostic and treatment biomarkers, progress in determining the role of the genome in drug metabolism heralds the first effort in personalized prescribing for the antidepressants. The FDA suggested and approved genotyping tests for common variants of drug metabolism genes, such as the cytochrome p450s. By using these tests a physician can select an appropriate antidepressant for a given patient, as differences in clearance, half-life, and peak blood concentrations are controlled by genetic variability in drug metabolism. Personalization in drug choice can be achieved because these tests: (1) identify responders and non-responders; (2) provide alerts to possible adverse drug events; and (3) help optimize dose. Improved ways of diagnosing and prescribing effective treatments for MDD are needed, as the available methods are inadequate and symptom based. In the foreseeable future, further interrogation of the genome may serve as the basis for development of new personalized medicine strategies for diagnosis and treatment of MDD.

show abstract

“…The screening of the depression like disorder, diagnose of the disorder, assessment of severity of disorder, and the measurement of changes in severity of disorders represent the main purpose of assessment of the scales for depression (Furukawa 2010). The psychiatric assessments can be organized in two formats: clinician-rated and self-report (Furukawa 2010).…”

Section: Assessment Of Depression In Glaucoma Patientsmentioning

confidence: 99%

“…Hamilton Depression Rating Scale (HDRS) is clinician-rated scale with 21 items for assessing the severity and measuring the changes of depression (Furukawa 2010, Cumurcu et al 2014. Montgomeri-Asberg Depression Rating Scale (MADRS) is clinician-rated instrument created with the purpose of measuring the severity and changes of depression (Furukawa 2010 The purpose of PHQ-9 is self-reported screening of depression, measuring of severity and measuring of changes in depression.…”

Section: Assessment Of Depression In Glaucoma Patientsmentioning

confidence: 99%